Results 121 to 130 of about 75,135 (288)
Evaluation of the first automated thyroglobulin assay [PDF]
, 1999 The aim of this study was to investigate technical and analytical performance of the first automated thyroglobulin (Tg) assay (DPC-Immulite(R); Diagnostic Products Corporation, Los Angeles, USA).
Jacob, Karl +3 more
core +1 more source
Thyroidectomy with or without Radioiodine in Patients incidentally discovered with low papillary Thyroid Cancer [PDF]
Al-Azhar International Medical JournalBackground: The initial tumour's histology is the most crucial determinant of prognosis for thyroid cancer. Papillary and follicular thyroid cancers are thyroid tumours originating from follicular cells and accounting for 90% of all thyroid cancers.
doaj +1 more source
Allergy, EarlyView.ABSTRACT This update and revision of the international guideline for urticaria was developed in accordance with the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is an initiative of the Global Allergy and Asthma Excellence Network (GA2LEN) and its Urticaria and ...
T. Zuberbier +221 more
wiley +1 more source
Skip Metastases in Papillary Thyroid Cancer
Collegium antropologicum, 2013 Papillary thyroid carcinoma (PTC) is the most common malignant thyroid disease characterized by a high rate of cervical metastases (30-80%), especially due to paratracheal lymph node involvement. "Skip metastasis" are defined as a lateral lymph node metastasis without central lymph node involvement.
Klišeska, Elena, Makovac, Irena
openaire +3 more sources
A Spotlight on Yolk‐sac Tumors: Molecular Pathology, Current Diagnostics, and Novel Therapeutics
Andrology, EarlyView.ABSTRACT Background Yolk‐sac tumors are an aggressive subtype of testicular cancer that significantly contribute to disease progression and therapy resistance, especially in adults. While testicular cancer generally has high cure rates with cisplatin‐based treatment, adult yolk‐sac tumors often appear as components of mixed tumors with poor response to
Evangelos Prokakis +3 more
wiley +1 more source
Targeting KRAS for cancer therapy
British Journal of Pharmacology, EarlyView.In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia +4 more
wiley +1 more source
NECTIN4 promotes papillary thyroid cancer cell proliferation, migration, and invasion and triggers EMT by activating AKT [PDF]
, 2019 Ru-Tian Hao, Chen Zheng, Chen-Yong Wu, Er-Jie Xia, Xiao-Fen Zhou, Rui-Da Quan, Xiao-Hua ZhangDepartment of Thyroid and Breast Surgery, The First Affiliated Hospital of Wenzhou, Medical University, Wenzhou, Zhejiang, People’s Republic of ...
Zhou XF +6 more
core
CD93—An emerging vascular target in cancer therapy
British Journal of Pharmacology, EarlyView.Abstract CD93 is a single‐pass transmembrane glycoprotein that belongs to the C‐type lectin domain group XIV family of proteins. Although it is known to be expressed in other cell types, namely, in some subsets of immune cells, CD93 is primarily expressed on endothelial cells, where it acts as a crucial regulator of angiogenesis.
Beatriz de Alves Pereira +3 more
wiley +1 more source
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium [PDF]
, 2006 Thyroid carcinoma is rare among human malignancies (
EUROPEAN +7 more
core